Our tests and services

All of us have a 1 in 2 lifetime risk of developing cancer, but some are known to occur more frequently in families, passing down the generations. This test analyses 30 genes associated with the most common hereditary cancers.

If you have already been diagnosed with cancer, this test is a rapid analysis that can help you make vital decisions about your treatment – particularly if you are considering surgical options.

All of us have a 1 in 2 lifetime risk of cancer, but some common cancers – breast, melanoma, pancreatic, prostate and ovarian – are known to occur more frequently in families, passing from one generation to the next. It’s because certain gene mutations can be inherited – particularly those in BRCA1 and BRCA2 genes – and this test focuses on these, pus another six genes which can indicate additional risk.

If you have Stage II or Stage III colon cancer, this test can be used to understand the risk of your cancer recurring and therefore enable you make informed decisions about your personal treatment options. It is particularly valuable in assessing whether chemotherapy is necessary or appropriate when you have Stage II colon cancer.

Learn whether PARP inhibitors – one of the latest treatments available – could help you fight ovarian epithelial cancer with this two-gene test focusing on BRCA 1 and BRCA 2.

Ask about our wider 11-gene test which looks at factors including whether PARP inhibitors – one of the latest treatments available in fighting ovarian epithelial cancer – can help you.

If you’re a woman with early-stage, hormone-receptor-positive breast cancer, this test can help you and your clinician identify the best treatment options for you, particularly around the length of time it’s beneficial to have hormonal therapy.

If you have been diagnosed with the blood cancer, multiple myeloma, this test can help your clinician select the best treatment for you.

If you have been diagnosed with colorectal or endometrial cancer with abnormal MSI and/or Immunohistochemistry (IHC) results, this test can help you make key decisions about your treatment.

If you have been diagnosed with colorectal or endometrial cancer with abnormal MSI and/or IHC results, this test can help inform key treatment decisions.